Who are Genetic: AAV5-hRKp.RPGR Intermediate Dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Genetic: AAV5-hRKp.RPGR, Genetic: AAV5-hRKp.RPGR Low Dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/genetic-aav5-hrkp-rpgr-intermediate-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Genetic: AAV5-hRKp.RPGR Intermediate Dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genetic: AAV5-hRKp.RPGR Intermediate Dose (Genetic: AAV5-hRKp.RPGR Intermediate Dose) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gene therapy (AAV vector). Area: Ophthalmology / Retinal Diseases.

phase 3 Gene therapy (AAV vector) RPGR (retinitis pigmentosa GTPase regulator) gene Ophthalmology / Retinal Diseases Biologic Live · refreshed every 30 min

Target snapshot

Genetic: AAV5-hRKp.RPGR Intermediate Dose (Genetic: AAV5-hRKp.RPGR Intermediate Dose) — Janssen Research & Development, LLC. AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Genetic: AAV5-hRKp.RPGR Intermediate Dose TARGET	Genetic: AAV5-hRKp.RPGR Intermediate Dose	Janssen Research & Development, LLC	phase 3	Gene therapy (AAV vector)	RPGR (retinitis pigmentosa GTPase regulator) gene
Genetic: AAV5-hRKp.RPGR	Genetic: AAV5-hRKp.RPGR	Janssen Research & Development, LLC	phase 3	Gene therapy (AAV vector)	RPGR (retinitis pigmentosa GTPase regulator) gene
Genetic: AAV5-hRKp.RPGR Low Dose	Genetic: AAV5-hRKp.RPGR Low Dose	Janssen Research & Development, LLC	phase 3	Gene therapy (AAV vector)	RPGR gene; photoreceptor cells

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gene therapy (AAV vector) class)

Janssen Research & Development, LLC · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Genetic: AAV5-hRKp.RPGR Intermediate Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/genetic-aav5-hrkp-rpgr-intermediate-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab